Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN40,2240,29-3,93
Msft209,72209,73-3,03
Nokia3,533,5655-0,57
IBM112,07112,1-3,41
Daimler AG47,8947,895-0,90
PFE37,8537,86-0,85
26.10.2020 20:17:45
Indexy online
AD Index online
select
AD Index online
 

  • 26.10.2020 20:16:28
Five Prime Ther (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
5,47 -1,80 -0,10 300 963
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 26.10.2020
Popis společnosti
Obecné informace
Název společnostiFive Prime Therapeutics Inc
TickerFPRX
Kmenové akcie:Ordinary Shares
RICFPRX.O
ISIN-
Prioritní akciePreference Shares Series A
Prioritní akciePreference Shares Series A1
Prioritní akciePreference Shares Series A2
Prioritní akciePreference Shares Series A3
Poslední známé roční výsledky31.12.2019
Poslední známé čtvrtletní výsledky30.06.2020
Počet zaměstnanců k 31.12.2019 87
Akcie v oběhu k 31.07.2020 36 627 925
MěnaUSD
Kontaktní informace
Ulice111 Oyster Point Blvd
MěstoSOUTH SAN FRANCISCO
PSČ94080-1910
ZeměUnited States
Kontatní osobaMartin Forrest
Funkce kontaktní osobyVP, Investor Relations & Corporate Communications
Telefon14 153 655 600
Fax14153655601

Business Summary: Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s primary focus is on researching and developing immuno-oncology and targeted cancer therapies. The Company’s pipeline includes Bemarituzumab (FPA144), which is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that it is studying in a clinical trial in combination with 5-fluorouracil (5-FU), leucovorin and oxaliplatin; FPA150, which is a CD8 T cell checkpoint inhibitor antibody that targets B7-H4; FPT155, which is a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28; Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials, and BMS-986258, which is an anti-T cell immunoglobulin and mucin domain-3, or TIM-3 antibody.
Financial Summary: BRIEF: For the six months ended 30 June 2020, Five Prime Therapeutics Inc revenues increased 36% to $11.8M. Net loss decreased 47% to $37.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Stock-based Compensation in R&D decrease of 62% to $1.7M (expense), Stock-based Compensation in SGA decrease of 22% to $5M (expense), Other expense.
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICS2007Research and Development in Biotechnology
NAICS2007Pharmaceutical Preparation Mfg
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Pharmaceutical Preparation Manufacturing
SICCommercial Physical Research
SICPharmaceutical Preparations



  • Poslední aktualizace: 26.10.2020
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive OfficerThomas Civik5113.04.202013.04.2020
Chief Financial Officer, Executive Vice PresidentDavid Smith6028.02.201926.11.2018
Executive Vice President, Chief Medical OfficerHelen Collins5720.08.201920.03.2017
Chief Strategy Officer and SecretaryFrancis Sarena49